IL6 and hepatocellular carcinoma: A prospective cohort study in Korea involving 165 patients with advanced HCC treated with atezolizumab and bevacizumab revealed that serum IL-6 concentrations were markedly higher in participants who did not experience any clinical benefits within six months of systemic therapy initiation [46].